The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

While there are hundreds of methods to make the scale move, many cost hundreds of dollars. That’s why Amazon shoppers are ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...